Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Deffered Revenue (2016 - 2017)

Aptevo Therapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $2.8 million for Q2 2017.

  • For Q2 2017, Non-Current Deffered Revenue fell 16.29% year-over-year to $2.8 million; the TTM value through Jun 2017 reached $2.8 million, down 16.29%, while the annual FY2016 figure was $2.9 million, 12.72% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2017 was $2.8 million at Aptevo Therapeutics, roughly flat from $2.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $3.3 million in Q2 2016 and bottomed at $2.8 million in Q2 2017.
  • The 3-year median for Non-Current Deffered Revenue is $3.0 million (2016), against an average of $3.0 million.
  • The largest annual shift saw Non-Current Deffered Revenue dropped 12.72% in 2016 before it decreased 16.29% in 2017.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $3.3 million in 2015, then decreased by 12.72% to $2.9 million in 2016, then decreased by 3.45% to $2.8 million in 2017.
  • Per Business Quant, the three most recent readings for APVO's Non-Current Deffered Revenue are $2.8 million (Q2 2017), $2.8 million (Q1 2017), and $2.9 million (Q4 2016).